The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...

why do some patients benefit from immunotherapy while others do not? The current treatment for relapsed AML, donor lymphocyte infusion (DLI)--a therapy involving donor immune cells--has a 5-year ...

In cancer immunotherapy, T cells are often the stars of the show ... cells when he realized that they offered a unique opportunity to treat blood cancers like acute myeloid leukemia (AML). Previous ...

Acute myelogenous leukemia (AML) is seen in this stock image. Duke researchers have discovered a new combination of drugs ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

With 15 autologous and off-the-shelf cell therapy programs for a wide array of hematologic malignancies and solid tumors, Avalon is expanding horizons in cancer immunotherapy and cellular medicine.

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

Innate Pharma’s lirilumab – a cancer immunotherapy being developed in partnership with Bristol-Myers Squibb – has failed in a phase 2 blood cancer trial. Top-line results from the randomised ...